EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Open Access · CC BY 4.0

Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial

Senna W M Lammers, Sandra M E Geurts, Karlijn E P E Hermans, Irene E G van Hellemond, Astrid C P Swinkels, Carolien H Smorenburg, Maurice J C van der Sangen, Judith R Kroep, Aafke H Honkoop, Franchette W P J van den Berkmortel, Wilfred K de Roos, Alexander L T Imholz und 3 weitere

Breast Cancer Research and Treatment · 2024

DOI: 10.1007/s10549-024-07411-w ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Breast Cancer Research and Treatment, 2024. Verfasst von Senna W M Lammers und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, the Netherland…. Hauptthemen laut MEDLINE: Anastrozole, Breast Neoplasms, Triazoles, Nitriles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: AstraZeneca.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Patients with chemotherapy-induced ovarian function failure (CIOFF) may experience ovarian function recovery (OFR). Earlier, we showed that OFR during treatment with anastrozole impacted the prognosis of hormone receptor-positive (HR+) breast cancer (BC) patients with CIOFF. Here, we present the long-term follow-up results.

Methods

Postmenopausal women with HR+ BC who were 45–57 years of age and received chemotherapy were identified from the phase 3 DATA study (NCT00301457) on the extended use of anastrozole. Eligible patients were categorised into two groups: patients with CIOFF and definitely postmenopausal patients. Patients with CIOFF were monitored for OFR. Disease-free survival (DFS), distant recurrence-free survival (DRFS), and overall survival (OS) were compared between patients with OFR and patients without OFR using multivariable Cox regression analyses, including OFR as a time-dependent covariate. BC-specific mortality (BCSM) was compared between groups using the Fine and Gray method.

Results

This study included 656 patients: 395 patients with CIOFF and 261 definitely postmenopausal patients. OFR occurred in 39 (12%) of 329 patients with CIOFF who were monitored for OFR. The median follow-up time was 13.3 years. Patients with OFR experienced a deterioration in DFS (hazard ratio (HR) = 1.54; 95% confidence interval (CI) 0.85–2.81), DRFS (HR = 1.51; 95% CI 0.73–3.11), OS (HR = 1.64; 95% CI 0.75–3.55), and BCSM (subdistribution HR = 1.98; 95% CI 0.84–4.63) when compared with patients without OFR.

Conclusion

In patients with CIOFF, OFR during treatment with anastrozole was associated with a deterioration in BC outcomes. These findings underscore the importance of adequate ovarian function suppression in this subgroup of patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnastrozoleBreast NeoplasmsTriazolesNitrilesOvaryHumansFemaleMiddle AgedChemotherapy, AdjuvantAntineoplastic Agents, HormonalPostmenopausePrognosisTreatment OutcomeFollow-Up Studies

Stichwörter der Autor:innen

Aromatase inhibitorsBreast neoplasmsChemotherapy-induced amenorrheaChemotherapy-induced ovarian function failureOvarian function recovery

Substanzen

AnastrozoleTriazolesNitrilesAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Department of Medical Oncology, Maastricht University Medical Centre, GROW, Maastricht University, P.O. Box 5800, 6202 AZ, Maastricht, the Netherlands.
  • Department of Medical Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Clinical Research Department, Netherlands Comprehensive Cancer Organisation (IKNL), Nijmegen, the Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, the Netherlands.
  • Department of Radiation Oncology, Catharina Hospital, Eindhoven, the Netherlands.
  • Department of Medical Oncology, Leiden University Medical Centre, Leiden, the Netherlands.

Förderung

  • AstraZeneca

Zitieren

APA

Lammers, S. W. M., Geurts, S. M. E., Hermans, K. E. P. E., van Hellemond, I. E. G., Swinkels, A. C. P., Smorenburg, C. H., van der Sangen, M. J. C., Kroep, J. R., Honkoop, A. H., van den Berkmortel, F. W. P. J., de Roos, W. K., Imholz, A. L. T., Vriens, I. J. H., Tjan-Heijnen, V. C. G., & Dutch Breast Cancer Research Group (BOOG) for the DATA investigators (2024). Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial. Breast Cancer Research and Treatment. https://doi.org/10.1007/s10549-024-07411-w

Vancouver

Lammers SWM, Geurts SME, Hermans KEPE, van Hellemond IEG, Swinkels ACP, Smorenburg CH, et al. Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial. Breast Cancer Research and Treatment. 2024. doi:10.1007/s10549-024-07411-w

BibTeX
@article{Lammers2024,
  author = {Lammers, Senna W M and Geurts, Sandra M E and Hermans, Karlijn E P E and van Hellemond, Irene E G and Swinkels, Astrid C P and Smorenburg, Carolien H and van der Sangen, Maurice J C and Kroep, Judith R and Honkoop, Aafke H and van den Berkmortel, Franchette W P J and de Roos, Wilfred K and Imholz, Alexander L T and Vriens, Ingeborg J H and Tjan-Heijnen, Vivianne C G and Dutch Breast Cancer Research Group (BOOG) for the DATA investigators, Dutch Breast Cancer Research Group (BOOG) for the DATA investigators},
  title = {Ovarian function recovery in breast cancer patients receiving adjuvant anastrozole treatment: updated results from the phase 3 DATA trial},
  journal = {Breast Cancer Research and Treatment},
  year = {2024},
  doi = {10.1007/s10549-024-07411-w}
}
Kostenlos starten →